Home > Healthcare > Pharmaceuticals > Finished Drug Form > Pigmentation Disorder Treatment Market

Pigmentation Disorder Treatment Market Share

Report ID: GMI8528
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Pigmentation Disorder Treatment Market Share

The competitive landscape of the market is characterized by the presence of established pharmaceutical companies vying for market share. Key players are engaging in strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their business portfolios. Also, the companies are actively adopting a multi-pronged approaches to address the rising demand for effective pigmentation disorder treatment.

Pigmentation Disorder Treatment Market Companies

Prominent players operating in the pigmentation disorder treatment industry are as mentioned below:

AbbVie Inc.
Candela Corporation
Cipher Pharmaceuticals Inc.
Galderma
GlaxoSmithKline (GSK)
Incyte
L'Oréal Paris
Novartis AG
Pfizer Inc.
Pierre Fabre group
Shiseido Company Limited

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global pigmentation disorders treatment market was valued at USD 7.1 billion in 2023 and is expected to reach USD 11.6 billion by 2032, backed by the increasing prevalence of pigmentation disorders, such as vitiligo, melasma, and post-inflammatory hyperpigmentation among others.

The drugs segment accounted USD 4 billion in 2023 and will record notable demand through 2032, owing to increased R&D activities and product launches by major players in the industry.

In 2023, North America pigmentation disorders treatment market share was around 42.2%, and is expected to show impressive growth through 2032, attributed to high healthcare expenditure, alongside advanced medical infrastructure in the region.

AbbVie Inc., Candela Corporation, Cipher Pharmaceuticals Inc., Galderma, GlaxoSmithKline (GSK), Incyte, L'Or